ACUTE MYELOID LEUKEMIA

This study tests a new drug combination for adults with a specific type of acute myeloid leukemia (CD123+ AML) who cannot receive intensive chemotherapy. The treatment adds tagraxofusp to two standard drugs (venetoclax and azacitidine) to see if it improves remission rates. About…

This study tests a new drug called revumenib in people with certain types of leukemia that have returned or not improved with standard treatments. The trial has two parts: first, finding the safest dose, then testing how well it works in four specific groups of patients. About 44…

This study tests a combination of interferon-γ and donor immune cells for adults whose acute myeloid leukemia or myelodysplastic syndromes have returned after a stem cell transplant. The goal is to see if this treatment can control the disease and improve survival. About 45 parti…

This phase 3 study tests whether adding the experimental drug APG-2575 (Lisaftoclax) to standard azacitidine helps older adults with newly diagnosed acute myeloid leukemia live longer. About 486 participants who cannot tolerate strong chemotherapy will receive either the combo or…

This study compares two treatment approaches for adults whose acute myeloid leukemia has returned or not responded to initial therapy. Participants will receive either a milder, low-intensity therapy or a stronger, high-dose chemotherapy. The goal is to see if the gentler option …

This study tests a refined cord blood transplant method for people with hard-to-treat blood cancers like leukemia and lymphoma. Participants receive chemotherapy and radiation before the transplant to kill cancer cells and prepare the body, then donor stem cells are infused to re…

This study tests a two-step method using lower doses of radiation and chemotherapy before a stem cell transplant for people with various blood cancers or bone marrow failure. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About…

This early-phase trial tests a special type of immune cell (CIML NK cells) combined with a low dose of IL-2 in people whose blood cancer (AML, MDS, MPN, or JMML) has returned after a stem cell transplant. The main goal is to find the safest dose and see if it can put the cancer b…

This early-stage study tests a new treatment called CER-1236 for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis) that have not responded to standard therapy. CER-1236 is made from a patient's own immune cells, which are modif…

This early-phase trial tests a new drug called HC-7366 in 18 adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find a safe dose and watch for side effects. Participants must have no other standard treatment options avai…

This study tests whether using a person's genetic risk for mold infections can help doctors choose the right antifungal medicine for patients with acute myeloid leukemia (AML) receiving chemotherapy. About 410 adults with AML will be randomly assigned to get either standard or ge…

This early-phase study tests a new drug called FHD-286 combined with two standard chemotherapy drugs (decitabine and venetoclax) in adults with acute myeloid leukemia (AML) that is high-risk or has returned after treatment. The main goals are to find the safest dose and watch for…

This study tests whether adding venetoclax to a standard chemotherapy regimen (FLAG IDA) helps more people with newly diagnosed acute myeloid leukemia (AML) achieve deep remission. About 102 adults aged 18 to 65 will be randomly assigned to the new combo or standard treatment. Th…

This study tests a new drug combination (ABC-14) for adults newly diagnosed with acute myeloid leukemia (AML). It compares the new combo to standard chemotherapy or another two-drug regimen. The goal is to see if the new approach leads to more complete remissions with fewer side …

This study tests whether a new chemotherapy combination (TmBU) works better than the standard one (mBUCY) before a stem cell transplant in people with high-risk or hard-to-treat leukemia. About 48 adults aged 65 or younger will be randomly assigned to one of the two regimens. The…

This early-phase trial tests whether combining two drugs—tagraxofusp and azacitidine—can safely prevent cancer from returning after a donor stem cell transplant in people with CD123-positive acute myeloid leukemia or myelodysplastic syndrome. About 43 adults aged 18 to 75 will re…

This study is for people with blood cancers like leukemia or lymphoma who need a stem cell transplant from an unrelated donor. It compares two ways to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. One method uses a d…

This study is testing a combination of three drugs—quizartinib, decitabine, and venetoclax—in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The goal is to see if the combination can shrink or control the cancer. The trial is for adults 60 and old…

This early-phase trial tests whether adding emapalumab to standard medications can safely prevent graft-versus-host disease (GVHD) in 15 adults with leukemia or myelodysplastic syndrome receiving a reduced-intensity donor stem cell transplant. Emapalumab blocks a protein that dri…

This study tests a drug called DASATINIB in people with acute myeloid leukemia (AML) whose cancer did not improve after standard treatment with VENETOCLAX and AZACITIDINE. About 35 adults who cannot have chemotherapy will take DASATINIB for up to 3 months. Doctors will check if t…

This program provides galinpepimut-S, an experimental immune therapy, to individual patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have run out of standard treatments. It is not a clinical trial but a way to access the drug when no other options …

This study tests an experimental oral drug called LP-118 in up to 100 adults with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to other treatments. The main goals are to find the safest dose and see if the drug can shrink tumors …

This study tests whether new drug combinations work better than standard therapy for children and young adults with newly diagnosed acute myeloid leukemia (AML). About 1,186 participants will receive either standard chemo plus gemtuzumab ozogamicin, or a newer drug called CPX-351…

This study tests a new drug, bleximenib, for people with acute leukemia that has come back or not responded to other treatments. The drug targets specific genetic changes in leukemia cells. The study has two phases: first to find the best dose and check safety, then to see how we…

This study tests a new drug called CCS1477 in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 250 participants will receiv…

This study compares two strategies to lower the risk of graft-versus-host disease (GVHD) in people with acute leukemia or myelodysplastic syndrome (MDS) who are getting a donor stem cell transplant. Participants will receive either a treatment that removes certain immune cells fr…

This study is for children whose acute myeloid leukemia (AML) has come back or not responded to treatment. It tests two oral drugs, venetoclax and ASTX727, given together to find the safest dose and see how well they work. About 40 children will take part, and the main goal is to…

This early-phase study is testing a new way to prepare donor stem cells, called Orca-Q, for people with certain blood cancers (like leukemia) who need a stem cell transplant. The goal is to see if this engineered graft is safe and helps the body accept the new cells without sever…

This study tests a personalized vaccine made from a patient's own leukemia cells to help prevent the cancer from coming back. It is for adults with acute myeloid leukemia who are in remission after standard chemotherapy. The vaccine aims to train the immune system to recognize an…

This study tests whether an oral medication (azacitidine) can help prevent acute myeloid leukemia from coming back in patients who are eligible for a stem cell transplant but cannot get one due to racial or socioeconomic reasons. About 12 adults whose leukemia is in remission wil…

This early-phase trial tests a new treatment for adults and teens with a hard-to-treat form of acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR T-cells) that target a protein called CD4…

This early-phase study tests the safety of giving special immune cells (CIML NK cells) along with a standard drug (venetoclax) to adults with acute myeloid leukemia (AML). The treatment aims to help the body's natural killer cells fight leukemia more effectively. About 10 partici…

This study tests a long-acting antibiotic called dalbavancin to prevent bacterial bloodstream infections in children and young adults with high-risk leukemia who are receiving strong chemotherapy. About 29 participants will receive the drug every 28 days. The goal is to see if it…

This study tests a new drug called sonrotoclax combined with standard chemotherapy and other targeted medicines for adults who have just been diagnosed with acute myeloid leukemia (AML). About 205 participants will receive different combinations based on their genetic markers. Th…

This early-phase study tests the safety of combining two chemotherapy drugs, CPX-351 and gemtuzumab ozogamicin, in adults aged 18 to 70 with newly diagnosed acute myeloid leukemia. The goal is to find the highest safe dose and see how well the combination works at achieving remis…

This study tests a new treatment called multi-CAR T cell therapy for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses specially engineered immune cells to target several markers on leukemia cells. The goal is to…

This early-stage study tests a combination of two drugs, bomedemstat and venetoclax, in adults with acute myeloid leukemia (AML) that has returned or not responded to prior therapy. The main goal is to find the safest dose and understand side effects. About 18 participants will b…

This study tests a new way to prepare donor stem cells for transplant in people with blood cancers like leukemia. By removing certain immune cells from the donated cells, researchers hope to lower the risk of graft-versus-host disease, a serious side effect. The study involves 70…

This study tests whether adding the drug venetoclax to standard chemotherapy helps children and young adults with relapsed acute myeloid leukemia (AML) live longer. About 130 participants aged 29 days to 21 years will be enrolled. The goal is to see if the combination improves su…

This early-stage trial tests a new drug called ziftomenib combined with two other medicines (venetoclax and gemtuzumab) in children and young adults aged 3 to 21 with acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find a safe do…

This study tests a completely oral combination of three drugs—SNDX-5613, decitabine/cedazuridine, and venetoclax—for people with acute myeloid leukemia (AML) or related leukemia. The goal is to find the best dose and see if the combo can control the disease. It is for newly diagn…

This study is for people with certain blood cancers (like leukemia) that have a specific genetic change called an IDH1 mutation. It tests a combination of two or three drugs: ivosidenib (targets the mutation), venetoclax (blocks a protein that helps cancer cells survive), and som…

This early-stage study tests a new drug called danvatirsen, first alone and then combined with venetoclax, in adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to standard treatments. The goal is to see if the treatme…

This early-phase study tests a drug called pemigatinib, which blocks a protein that helps leukemia cells grow. It is given after standard chemotherapy to adults newly diagnosed with acute myeloid leukemia (AML). The goal is to find the safest dose and see if it improves remission…

This study is testing a new drug called BGB-11417 for people with certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The goal is to find the safest dose and see if the drug works on its own or when combined with another cancer medic…

This early-phase study tests a new drug, SL-401, combined with standard treatments (azacitidine and venetoclax) for people with certain blood cancers like acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The g…

This early-stage study is testing a new drug called RPT1G in 24 people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) whose cancer has returned or not responded to standard treatments. The main goals are to check if RPT1G is safe and to find the be…

This study tests a combination of two drugs, enasidenib and azacitidine, in people with a high-risk form of myelodysplastic syndrome (MDS) that has a specific IDH2 gene mutation. The goal is to see if the treatment is safe and can shrink or control the cancer. About 63 participan…

This study tests a combination of two drugs, cladribine and venetoclax, in adults with a specific type of acute myeloid leukemia (monocytic AML) that came back or didn't respond to standard treatment. About 20 participants will receive the new drug combo to see if it can shrink o…

This early-phase study tests a new treatment for adults with acute myeloid leukemia or myelodysplastic syndrome who still have small amounts of cancer cells after standard therapy. The treatment uses a patient's own blood cells that are specially armed with a bispecific antibody …

This study tests whether adding the drug ruxolitinib to the usual two-drug regimen (tacrolimus and methotrexate) can better prevent graft-versus-host disease (GVHD) in children and young adults (ages 2-22) undergoing bone marrow transplant for leukemia or myelodysplastic syndrome…

This study tests whether giving a chemotherapy drug (decitabine) along with a JAK inhibitor (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPNs) get to transplant and have better outcomes. About 25 a…

This study tests a new combination of three drugs (TAGraxofusp, azacitidine, and venetoclax) for people with a type of acute myeloid leukemia (AML) that developed after prior treatment with similar drugs. The goal is to see if this combination can achieve complete remission. The …

This study tests whether a combination of two drugs, venetoclax and azacitidine, can eliminate small numbers of leftover leukemia cells (called measurable residual disease, or MRD) in people with acute myeloid leukemia (AML). These patients still have MRD after initial chemothera…

This early-stage trial tests a new type of immune cell therapy (called universal CAR T cells) for people with blood cancers like T-cell leukemia and lymphoma that have a specific marker called CD7. The therapy uses donor cells engineered to attack cancer cells. The study aims to …

This study tests a new approach for adults with aggressive blood cancers (like AML) that are hard to treat. Patients get a stronger chemotherapy mix (decitabine plus FLAG-Ida) and total body radiation, followed by a donor stem cell transplant. The goal is to kill cancer cells and…

This early-phase study tests whether adding high-dose vitamin C (ascorbate) to standard chemotherapy (azacitidine and venetoclax) is safe and works better for adults with newly diagnosed acute myeloid leukemia who cannot tolerate intensive chemo. About 30 participants will be ran…

This study tests whether adding venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) or related conditions live longer without the cancer returning. About 650 participants aged 18 to 75 will receive either venetoclax or a placebo alon…

This study tests a new combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a stem cell transplant in people aged 18-55 with intermediate or high-risk acute myeloid leukemia (AML) who have not been treated before. The goal is to see if this appr…

This early-phase study tests whether specially trained immune cells (CIML NK cells) given after a stem cell transplant can safely prevent leukemia or related blood cancers from coming back. About 15 adults with high-risk acute myeloid leukemia, myelodysplastic syndrome, or relate…

This early-phase study tests a new treatment called SC-DARIC33 for children and young adults up to age 30 whose acute myeloid leukemia (AML) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are genetically modified to be…

This study tests a new treatment plan for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3-ITD mutation. The goal is to see if a combination of targeted drugs (gilteritinib, venetoclax, and azacitidine) followed by high-dose chemotherapy can control the…

This early-phase trial tests a new drug called revumenib added to standard chemotherapy and a targeted therapy (midostaurin) for people with a specific genetic type of acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it works to put the cancer into r…

This early-stage study tests a new drug called STX-0712 in people with advanced chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) who have run out of standard treatments. The main goals are to find a safe dose and check for side effects. About 105 participant…

This early-phase study tests whether adding an experimental drug (defactinib) to an approved oral treatment (decitabine/cedazuridine) is safe and tolerable for people with high-risk myelodysplastic syndromes, certain acute myeloid leukemias, and chronic myelomonocytic leukemia. A…

This study tests a new combination of drugs for people newly diagnosed with a specific type of acute myeloid leukemia (AML). The treatment uses venetoclax, a targeted drug, along with chemotherapy drugs cladribine, cytarabine, and azacitidine. The goal is to see if this combinati…

This study looks at how the body handles the cancer drug ASTX727 in people with severe kidney impairment compared to those with normal kidneys. It includes adults with certain blood cancers or solid tumors. The goal is to understand safety and drug levels, not to cure the disease…

This study tests whether two drugs, venetoclax and revumenib, can control minimal residual disease (MRD) in acute myeloid leukemia (AML). MRD means a small number of cancer cells remain after treatment, raising relapse risk. The trial enrolls about 8 people aged 12 and older with…

This study tests whether giving two drugs (decitabine and filgrastim) after a stem cell transplant can safely prevent cancer from coming back in children and young adults with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or related blood cancers. About 37 partic…

This early-phase study tests a new treatment for acute myeloid leukemia (AML) that combines a personalized immune cell therapy with standard chemotherapy drugs. The therapy uses the patient's own immune cells, trained to attack the cancer, along with a vaccine to boost the immune…

This study tests a new drug called Debio 1562M in people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The first part finds a safe dose, and the second part checks if the drug can shrink or control the cancer. About 134 participants wi…

This early-phase trial is testing whether the drug olutasidenib can safely prevent blood cancers (AML, MDS, or CMML) from coming back after a donor stem cell transplant. The study includes 15 adults whose cancers have a specific IDH1 gene change. Participants will take olutasiden…

This early-phase trial is testing whether adding natural killer (NK) cells from a healthy donor to the usual drugs (azacitidine and venetoclax) can better control acute myeloid leukemia (AML). About 32 adults with AML that has returned or not responded to treatment will take part…

This study tests a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) in about 500 adults with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blast-phase chronic myeloid leukemia. The goal is to see how well these drugs kil…

This study tests a new treatment for adults with a rare form of acute myeloid leukemia (AML) that has a specific genetic change. Instead of standard strong chemotherapy, patients receive a combination of drugs including venetoclax. The goal is to see if this approach can achieve …

This study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk leukemias or related blood cancers. The antibody targets cancer cells and delivers radiation to help kill them while sparing healthy cells. The goal is to f…

This study tests whether adding a third drug (enasidenib) to the usual two-drug treatment (ASTX727 and venetoclax) can help more older adults with a specific genetic form of acute myeloid leukemia (IDH2-mutant AML) achieve complete remission. About 93 participants who are newly d…

This early-stage study tests a new drug called ziftomenib combined with standard treatments for people with a type of acute myeloid leukemia (AML) that has come back or not responded to therapy. The main goal is to check safety and find the best dose. About 171 adults with specif…

This study tests a new drug, venetoclax, added to standard chemotherapy for adults newly diagnosed with acute myeloid leukemia (AML) or advanced myelodysplastic syndrome (MDS). The goal is to find the safest and most effective dose. About 99 participants will receive the combinat…

This early-stage study tests a new oral drug, GLB-001, in about 48 adults whose acute myeloid leukemia or high-risk myelodysplastic syndromes have returned or not responded to other treatments. The main goals are to check safety, find the best dose, and see early signs of effecti…

This study tests the safety and effectiveness of the drug ponatinib in children aged 1 to under 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to other treatments. The goal is to see if ponatinib can shrink or control the cancer. About…

This study tests a two-step treatment for adults with a specific type of acute myeloid leukemia (AML) that has a mutation in the IDH1 gene. First, patients receive a combination of two drugs (olutasidenib and azacitidine) to control the cancer. Then, they continue on a maintenanc…

This study tests a combination of four drugs (venetoclax, cladribine, low dose cytarabine, and azacitidine) in adults aged 50 and older with untreated acute myeloid leukemia (AML). The goal is to see if this mix can kill cancer cells or stop them from growing. Participants will r…

This study watches adults in Korea who are already receiving Mylotarg for newly diagnosed acute myeloid leukemia (AML). Researchers will track side effects and how the disease responds. The goal is to learn more about the drug's safety and effects in real-world use. No new treatm…

This study tests whether a new drug called CPX-351 works better than standard chemotherapy for adults aged 50 and older with a newly diagnosed, aggressive form of acute myeloid leukemia (AML). About 248 participants will be randomly assigned to receive either CPX-351 or standard …

This early-stage trial tests a drug called talazoparib, combined with standard chemotherapy, for children and young adults up to age 21 whose acute myeloid leukemia (AML) has come back or not responded to treatment. The main goal is to find the safest dose and see if the combinat…

This study tests a low-dose weekly combination of two FDA-approved drugs, decitabine and venetoclax, for people with bone marrow cancers like MDS, AML, and CMML. The goal is to see if this gentler schedule can keep patients on treatment longer with fewer interruptions. About 91 a…

This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) is processed by the body in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to find safe dosin…

This study tests a combination of three drugs (olutasidenib, venetoclax, and azacitidine) in people with a specific genetic form of acute myeloid leukemia (IDH1 mutation). The goal is to see if this combo is safer and works better than standard intensive chemotherapy. About 16 ad…

This study is for children under 25 who have had a stem cell transplant for blood cancers like leukemia. After transplant, their immune system is weak, putting them at high risk for dangerous infections. Researchers are adding back a specific type of donor cell (CD45RA-depleted) …

This early-phase study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. About 12 patients will receive either strong or milder chemotherapy before the transplant. Researchers will monit…

This study tests a combination of three drugs (ASTX727, venetoclax, and either ivosidenib or enasidenib) in people with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if this mix is safe and can shrink or control the cancer. About 84 a…

This study tests an experimental drug called CTX-712 in adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have not responded to or returned after prior treatments. The goal is to find a safe dose and see if the drug can shrink or control the cancer.…

This study tests a new treatment for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better find and attack cancer cells. The go…

This study tests a targeted drug called gemtuzumab ozogamicin in adults with acute myeloid leukemia (AML) who have small amounts of cancer left after initial treatment. The drug attaches to a protein on leukemia cells and delivers chemotherapy directly to them. The goal is to see…

This early-stage trial tests a combination of CAR T cells that target different markers on leukemia cells in people with relapsed or hard-to-treat acute myeloid leukemia (AML). The goal is to see if this approach is safe and can shrink or eliminate the cancer. About 10 participan…

This study tests whether adding venetoclax to the standard chemotherapy given before a stem cell transplant can help prevent the cancer from coming back in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 participants aged 12 to 60 …

This study tests whether a low-dose, weekly chemotherapy combination (decitabine and venetoclax) given after a stem cell transplant can prevent relapse in people with high-risk acute myeloid leukemia or myelodysplastic syndromes. About 20 participants will receive the treatment f…

This study is for adults aged 59 and younger with a high-risk form of acute myeloid leukemia (AML) that is harder to treat. It compares the standard chemotherapy with several newer drug combinations to see which works better at shrinking the cancer. About 335 people will take par…

This early-stage study tests an experimental drug called ziftomenib added to usual treatments for acute myeloid leukemia (AML) in people with specific gene changes (NPM1 mutation or KMT2A rearrangement). About 420 adults with newly diagnosed or returning AML will receive ziftomen…

This study tests whether adding the experimental drug bleximenib to standard chemotherapy improves outcomes for adults with newly diagnosed acute myeloid leukemia (AML) that has a KMT2A rearrangement or NPM1 mutation. Bleximenib blocks a protein interaction that helps leukemia ce…

This study tests whether specially trained immune cells from a half-matched donor can safely treat acute myeloid leukemia (AML) that has come back or not responded to standard therapy. About 20 people aged 2 and older with AML will receive an infusion of these cells. The main goa…

This early-stage trial tests a new drug called SEA-CD70, alone or with other medicines, in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goals are to find safe doses and check for side effects. About 178 adults whose cancer has returned or n…

This study tests adding venetoclax to a standard chemotherapy regimen (CLAG-M) for people with acute myeloid leukemia (AML) or related high-grade blood cancers. The goal is to find the safest dose and see if the combination improves cancer control. About 62 participants will be e…

This early-phase study tests a new treatment for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack leukemia cells. The main goals…

This study tests whether combining two drugs, revumenib and mezigdomide, is safe for people whose acute leukemia has returned or not responded to prior treatment. It includes adults and teens aged 12+ with specific genetic subtypes (KMT2A-r, NUP98-r, or NPM1-m). The first part fi…

This study tests whether adding venetoclax to standard chemotherapy helps more younger adults with intermediate-risk acute myeloid leukemia (AML) achieve deep remission where no cancer cells can be detected. About 153 participants will receive either standard chemo alone, standar…

This study tests whether a drug called romiplostim N01 can help rebuild platelets faster after a stem cell transplant for blood cancers like leukemia. About 130 adults will receive either the drug or standard care. The goal is to see if the drug reduces bleeding risk and speeds r…

This study tests a new treatment called ADCLEC.syn1 CAR T cells for adults whose acute myeloid leukemia (AML) has come back or not responded to standard therapy. The main goal is to find a safe dose that causes few side effects. About 40 participants will receive the cells, and r…

This study tests whether giving special immune cells (NK cells) before and after a stem cell transplant can help prevent leukemia from coming back in children and young adults (ages 0–25) with hard-to-treat acute leukemia. The NK cells are grown in a lab and come from the same do…

This early-phase study tests whether adding a radioactive antibody (225Ac-DOTA-daratumumab) to standard chemotherapy and radiation before a donor stem cell transplant is safe and effective for people with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, or myelodys…

This study tests two different doses of quizartinib as a maintenance treatment for adults with a specific type of acute myeloid leukemia (FLT3-ITD positive) who are in their first complete remission and have not had a stem cell transplant. The goal is to see which dose is safer a…

This early-phase trial tests whether replacing two standard chemotherapy cycles with new drug combinations can work as well or better for children with acute myeloid leukemia (AML) while causing fewer long-term problems. About 36 children and young adults up to age 30 with interm…

This early-phase trial tests a combination of three drugs (pembrolizumab, decitabine, and venetoclax) in adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to prior treatment. The goal is to find the safest dose and see how well the …

This early-stage study tests whether drugs that remove extra metals from the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. Researchers want to find the safest dose and see if lowering metal levels in blood…

This early-stage study tests a new type of stem cell transplant for children whose blood cancer or solid tumor has returned or is hard to treat. Doctors use a special method to remove certain immune cells from the donor's stem cells, then give a drug called zoledronate after tran…

This study tests whether adding silibinin (a liver-protecting supplement) to standard chemotherapy can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). About 100 adults will be randomly assigned to receive chemo with or without silibinin. The goal is…

This study tests a stem cell transplant from a half-matched donor for people with blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare the body. The goal is to see if this approach helps the new stem cells grow and fight cancer wit…

This study is for older adults with a specific genetic form of acute myeloid leukemia (IDH-mutated AML) who cannot have strong chemotherapy. It compares two treatment sequences: one starting with a targeted IDH inhibitor followed by a standard combo, and the other starting with t…

This study is for people aged 16 to 70 with acute myeloid leukemia (AML) that has returned or not improved after standard treatment. Researchers are testing a combination of three drugs (venetoclax, cladribine, and low-dose cytarabine) to see if it can shrink or eliminate the can…

This early-stage trial tests a cell therapy called Orca-T combined with standard drugs to prevent graft-versus-host disease (GVHD) in up to 24 adults with advanced blood cancers like leukemia or MDS. Participants receive a stem cell transplant from a donor who is only a 7 out of …

This study tests whether a three-drug combination (ivosidenib, azacitidine, and venetoclax) followed by maintenance therapy with ivosidenib alone can help keep acute myeloid leukemia (AML) with an IDH mutation from coming back. It includes 45 adults aged 60 or older with newly di…

This study tests a combination of three treatments—a PD-1 inhibitor, azacitidine, and low-dose donor lymphocyte infusion—in people whose acute myeloid leukemia has returned after a stem cell transplant. The goal is to see if this approach can help control the leukemia and improve…

This study tests whether giving two common heart medications (a beta blocker and an ACE inhibitor) during intensive chemotherapy can prevent heart damage in people newly diagnosed with acute myeloid leukemia (AML). About 70 adults will be randomly assigned to receive the heart dr…

This study tests whether a maintenance drug called HMA can help people with a favorable type of acute myeloid leukemia (AML) stay in remission longer and live longer. About 77 adults who have already achieved remission after initial treatment will receive HMA therapy. The goal is…

This early-stage trial tests a new antibody drug called GEN3018 in people whose acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) has returned or stopped responding to treatment. The main goal is to check safety and find the right dose for future studies.…

This early-stage study tests whether adding two drugs, decitabine and venetoclax, to a standard stem cell transplant can make the procedure safer for people with aggressive blood cancers like leukemia. About 20 adults aged 18-75 with a matched donor will receive the experimental …

This study tests a combination of two drugs—CPX-351 (a stronger form of standard chemo) and quizartinib (a targeted therapy)—in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to find the safest dose and see if the combo can bette…

This study looks at whether people with acute myeloid leukemia (AML) who are already responding well to a combination of two drugs (venetoclax and azacitidine) can safely stop taking them. About 50 adults who have been on this treatment for a year and are in remission will stop t…

This study tests a drug called enasidenib given after a donor stem cell transplant to people with a specific genetic form of acute myeloid leukemia (IDH2 mutation). The goal is to see if it safely helps prevent the cancer from coming back. About 35 participants will take enasiden…

This study tests an oral drug (ASTX030) that combines two medicines to treat certain blood cancers like MDS and AML. The goal is to see if taking a pill works as well as getting a shot, and if it can be safely combined with another drug (venetoclax) for AML. About 316 adults will…

This early-stage study tests a new drug called cirtuvivint, alone or with another drug (ASTX727), in people with certain blood cancers (MDS and AML). The goal is to find a safe dose and see how well it works. About 54 adults whose cancer has returned or not responded to treatment…

This study tests a combination of four drugs (cladribine, idarubicin, cytarabine, and quizartinib) in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that is either newly diagnosed or has returned/not responded to treatment. The goal is to see…

This early-phase study tests a new drug called Q702 combined with two standard leukemia medicines (azacitidine and venetoclax) in 32 adults whose acute myeloid leukemia has returned or not responded to prior treatments. The main goal is to check the safety and side effects of thi…

This study tests whether a donor stem cell transplant after chemotherapy can prevent leukemia from coming back in people with a high-risk type of acute myeloid leukemia. About 90 newly diagnosed adults will receive one round of chemo, then two more rounds, followed by a transplan…

This study tests whether adding a targeted drug (gilteritinib) to the usual two-drug therapy (azacitidine and venetoclax) can help older or less-fit adults with a specific genetic form of acute myeloid leukemia (FLT3-mutated AML) achieve a deeper remission. About 147 participants…

This early-phase trial is testing an experimental oral drug, MRX-2843, in adolescents and adults whose acute leukemia has returned or not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 50 participants will take the dr…

This study tests whether adding two targeted drugs, midostaurin and gemtuzumab ozogamicin, to standard chemotherapy can improve outcomes for adults newly diagnosed with acute myeloid leukemia (AML) who have certain genetic changes. The trial has two phases: first to find the safe…

This study looks at whether people with acute myeloid leukemia (AML) whose cancer is well-controlled can stop their chemotherapy drugs (azacitidine or decitabine plus venetoclax) for a while without the leukemia coming back. Participants must be in remission with no detectable ca…

This study tests a combination of three drugs (ASTX727, venetoclax, and gilteritinib) for people with acute myeloid leukemia or high-risk myelodysplastic syndrome that has a specific gene change called FLT3. The goal is to find the best dose and see how well the drugs work togeth…

This study tests a three-drug combination (chidamide, venetoclax, and azacitidine) in adults with acute myeloid leukemia whose cancer did not respond to the first round of venetoclax and azacitidine. The goal is to see if adding chidamide can improve remission rates. About 32 par…

This study is for people with certain blood cancers (like leukemia) who are getting a half-matched bone marrow transplant. Researchers are adding a dose of specially grown immune cells (gamma delta T-cells) after the transplant to see if it can kill any leftover cancer cells whil…

This early-phase study tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…

This study compares a new treatment (venetoclax plus the CACAG regimen) to the standard chemotherapy ("3+7") for adults aged 14-75 with newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if the new combination leads to more complete remiss…

This study tests whether giving special immune cells (memory-like NK cells) after a stem cell transplant can help control high-risk acute myeloid leukemia (AML) in children and adults. About 68 participants will receive donor stem cells followed by these NK cells. The goal is to …

This study tests a new experimental drug called EP0042, alone or with other cancer treatments, in adults with advanced acute myeloid leukemia (AML) or related blood cancers. The main goal is to find a safe dose that might work against the cancer. About 70 people will take part in…

This study tests a treatment for adults aged 60 and older with newly diagnosed, high-risk acute myeloid leukemia (AML) or similar blood cancers. The approach combines strong chemotherapy (FLAG-Ida) with a donor stem cell transplant shortly after, aiming to shorten the dangerous p…

This early-phase study tests a new drug called rezatapopt combined with azacitidine in people with a specific genetic mutation (TP53Y220C) linked to acute myeloid leukemia or myelodysplastic syndrome. The goal is to see if the combination is safe and can help control the disease …

This early-phase trial tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize an…

This study tests a stem cell transplant using a milder chemotherapy combination (treosulfan and fludarabine) followed by donor stem cells and drugs to prevent graft-versus-host disease. It includes 132 people aged 2-75 with blood cancers like AML or MDS. The goal is to see if thi…

This early study tests a new drug called BMS-986497 in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer has returned or not responded to other treatments. The drug is given alone or together with standard medicines (azacitidine and venetocla…

This study tests a combination of two drugs, venetoclax and azacitidine, in about 100 Indian adults newly diagnosed with acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see how well the combo controls the cancer and what…

This study tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) in adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if the combo can wipe out hidden cancer cells and keep them away. About 10 participants…

This early-phase trial tests two oral drugs (ziftomenib and quizartinib) together in adults with relapsed or hard-to-treat acute myeloid leukemia (AML). The goal is to find a safe and effective all-pill treatment for common AML subtypes. About 44 participants will be enrolled.

This study is for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who have received a stem cell transplant from a half-matched donor. After the transplant, participants will receive extra immune cells called natural killer (NK) cells from the same dono…

This study tests whether a drug called dexrazoxane can protect the heart from damage caused by chemotherapy in people with certain blood cancers, like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). About 100 participants will receive dexrazoxane alongs…

This early-phase study tests whether a daily pill called olutasidenib can safely help adults with a specific type of acute myeloid leukemia (IDH1-mutant AML) stay in remission after standard chemotherapy. About 15 participants will take the drug for at least 4 months while doctor…

This early-phase study tests an experimental drug called ziftomenib in adults with acute myeloid leukemia (AML) who have had a stem cell transplant. The goal is to find a safe dose and see if the drug can help prevent the cancer from coming back. About 22 participants will take t…

This study tests whether adding venetoclax to standard chemotherapy before a stem cell transplant can help people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) live longer without their cancer coming back. About 324 adults aged 18 to 70 will receiv…

This early-phase study tests the safety and best dose of revumenib, a drug that blocks a protein fueling leukemia growth, in 27 adults and children with specific genetic types of acute leukemia. Participants take revumenib after a stem cell transplant to help keep the cancer from…

This study tests a daily pill (decitabine) given alone or with other targeted drugs to adults whose acute myeloid leukemia (AML) is in remission. The goal is to see if this maintenance therapy is safe and can help prevent the cancer from returning. About 125 participants will be …

This early-phase study tests a new stem cell treatment called Orca-T, combined with targeted radiation and chemotherapy, for people aged 60-75 with acute leukemias or myelodysplastic syndrome (MDS). The goal is to find the safest dose and see how well the body tolerates the treat…

This study tests whether giving a CMV vaccine to stem cell donors can protect transplant recipients from CMV infection. Donors receive the vaccine before donating stem cells, and the immunity is passed to the patient. The trial involves 216 people with blood cancers and aims to r…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after transplant. About 46 people with various blood cancers or disorders will take part. The goal i…

This study looks at whether giving blood transfusions at home is practical and acceptable for people with blood cancers or bone marrow failure who need regular transfusions. About 30 adults will receive 1-5 blood product units at home, and researchers will track how often transfu…

This study tests whether tranexamic acid, a medicine that helps blood clots stay in place, can reduce bleeding in people with myelodysplastic syndromes or acute myeloid leukemia who are on chemotherapy. About 75 adults with low platelet counts will be randomly assigned to receive…

This study looks at whether massage therapy can improve sleep for children aged 12 to 21 who are in the hospital for cancer treatment or a stem cell transplant. About 70 participants will either receive standard care or add massage therapy to their routine. Researchers will track…

This study looks at how radiation and chemotherapy change the bone marrow in people with acute leukemia. Researchers will use special scans and collect blood and bone marrow samples to track these changes over time. The goal is to learn more, not to test a new treatment. About 74…

This study examines stored umbilical cord blood from 300 children who later developed leukemia. Researchers will check the cord blood for the same genetic changes found in the children's leukemia cells. The goal is to understand how and when these changes first appear before birt…

This study is creating a large database of people with various blood diseases in China, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, out…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of mu…

This study looks at whether offering personalized financial navigation alongside standard care can lower the financial stress (called financial toxicity) felt by adults aged 18-64 who are being treated for acute myeloid leukemia. About 120 participants will be randomly assigned t…

This study collects blood and bone marrow samples from 80 adults with newly diagnosed acute myeloid leukemia (AML) who are receiving azacitidine plus venetoclax. Researchers will analyze the immune profile to understand how the body responds to treatment. The goal is to use this …

This study looks at whether giving red blood cell transfusions only when hemoglobin drops below 7 gm/dL (instead of 9 gm/dL) is safe and maintains quality of life in adults with acute leukemia or related cancers who have had chemotherapy or a stem cell transplant. About 50 partic…

This study follows people with inherited gene changes (DDX41) that raise the risk of blood cancers like MDS and AML. Researchers will track health over 10 years using exams, blood tests, and optional bone marrow biopsies. No treatment is given; the goal is to understand how these…

This study uses three types of advanced body scans (PET/MR, PET/CT, and whole body MRI) to find leukemia that has spread outside the bone marrow in people newly diagnosed with acute myeloid leukemia (AML). About 77 participants will receive these scans to see how well they detect…

This study is testing whether a special PET scan called 18F FLT can detect signs of leukemia or related blood cancers after treatment. About 60 people aged 4 to 80 with relapsed or hard-to-treat leukemia or myeloma will get the scan before and after therapy. The goal is to see if…

This study looks at memory, concentration, and language problems caused by chemotherapy in people with blood cancers like leukemia and lymphoma. Researchers will compare 120 patients to their healthy relatives using tests and questionnaires before and after treatment. The goal is…

This study is for people with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS). It uses special lab tests to find tiny amounts of cancer cells that may remain after treatment. The goal is to see if these tests can predict who is at higher risk of the dise…

This study is for people with acute myeloid leukemia (AML) who are getting a stem cell transplant. Researchers will use advanced genetic testing to track changes in immune cells (T-cells) before and after the transplant. The goal is to learn how the immune system affects recovery…

This study screens children and young adults (under 22) with leukemia that has returned or is difficult to treat. By analyzing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to …

This study looks at whether a new whole genome sequencing test called ChromoSeq can find more genetic changes in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) than current standard tests. Researchers will compare ChromoSeq results to conventional meth…

This study looks at whether measuring certain proteins in the blood can help predict outcomes for people with acute myeloid leukemia, high-risk myelodysplastic syndrome, or chronic myelomonocytic leukemia who receive a gentler type of chemotherapy. Researchers will collect blood …

This study is for adults with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have not yet received treatment. Researchers will test blood and bone marrow samples for specific biomarkers to see if participants can join a treatment trial that tar…

This study looks at people with neuroendocrine tumors (NETs) who are getting or have gotten peptide radionuclide therapy (PRRT). The goal is to find early warning signs in the blood that might show who is at higher risk of developing blood cancers like myelodysplastic syndrome (M…

This study looks at whether finding leukemia stem cells in the blood and bone marrow can better predict when childhood acute myeloid leukemia will come back. About 283 children newly diagnosed with AML will be followed to see if these cells are more accurate than current tests. T…

This study tests a telehealth program to help older patients (60+) with blood cancers like leukemia and MDS communicate better with their doctors and complete advance care plans. About 207 patients and their caregivers will be randomly assigned to the program or usual care. The g…

This study looks at how the body absorbs, breaks down, and gets rid of a radioactive form of the drug bleximenib in 10 people with acute leukemia. Participants have a type of leukemia that has come back or not responded to other treatments. The goal is to understand the drug's pa…

This study looks at how the drug venetoclax behaves in the bodies of people with acute myeloid leukemia (AML). Researchers will take extra blood samples to measure drug levels and see how they relate to treatment response. About 100 adults starting venetoclax plus azacitidine wil…

This study uses artificial intelligence and real-world patient data to compare a new drug combination (venetoclax plus decitabine) against standard chemotherapy for elderly patients (ages 60-75) with acute myeloid leukemia (AML). Researchers will analyze records from nearly 2,000…